Accelerating the Development of New Drugs from Preclinical Testing through First in Human to Proof of Concept

Oxford, United Kingdom | 27 March 2025
Overview

Join us for our seminar, "Accelerating the development of new drugs from preclinical testing through first in human to proof of concept".

The transition of new chemical entities from preclinical testing through the first in human study to proof-of-concept assessments is a well-established process but requires many risk based decisions in formulation and dose strength selection, protocol design and strategy to move to proof-of-concept. 

A Translational Pharmaceutics® project integrates formulation development, on demand drug product manufacture, and clinical testing to improve the conduct and outcomes from this key stage in any molecule’s development.

In this presentation, John McDermott will describe how Translational Pharmaceutics® enables development teams to:

  • Identify and select optimal formulations for preclinical and clinical testing
  • Simplify the CMC process needed to transition the drug into clinical development
  • Design and execute successful FIH protocols
  • Support switches of drug product type to meet emerging patient study needs
  • Enable seamless clinical trial supply to phase 2 and beyond
  • This integrated approach not only mitigates risks but also accelerates the pathway to proof-of-concept, ultimately enhancing the likelihood of success for new drug candidates
Date/AgendaLocation

Thursday, March 27th 2025

Registration: 5:30pm -6.30pm 

Seminar/Talk: 6:30pm - 7.00pm  

Networking Drinks: 7:00pm - 9:00pm   

Oxford Malmaison, Oxford Castle, 3 New Rd, Oxford OX1 1AY

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register
Location
Oxford Malmaison
Oxford Castle, 3 New Rd, OX1 1AY
Oxford, United Kingdom

Meet our expert:

We look forward to meeting you at our seminar in Oxford, United Kingdom.

John McDermott

Vice President, Scientific Consulting

John McDermott is Vice President of Scientific Consulting at Quotient Sciences. John leads Quotient Sciences' global drug developm...

About John

More insight from our experts:

Read More
Translational Pharmaceutics, Dr. Helen Baker, Dr. Vanessa Zann Accelerating Drug Development with Translational Pharmaceutics®
Read More
Translational Pharmaceutics, Denise Sutton, Nottingham, Clinical Pharmacology Spotlight on Nottingham: Q&A with Denise Sutton, Chief Operating Officer and Site Head - Nottingham, UK – Part 1 By: Denise Sutton
Read More
Get in touch
Humanity can't afford to wait, so neither can we.